MSB 0.68% $1.11 mesoblast limited

Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-218

  1. 120 Posts.
    lightbulb Created with Sketch. 122
    Perhaps someone more knowledgeable could clarify the following:

    • If at the 45% readout (or even the 60%) it is deemed that the treatment is showing outstanding results (as we all expect and hope for ) ie "Overwhelming efficacy" and the decision is made to continue the trial, does it continue with the placebo arm?
    • I ask as effectively that would be subjecting those remaining to be enlisted (to complete the trial) with a 50:50 chance of survival (obviously not exactly 50:50 due to improved SOC and Rem-l may not be 100% effective).
    • It does raise ethical questions

    • Is there any obligation to inform the market (company) or could/would they just announce "the trial is continuing" with out any reference to the results?
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.11
Change
0.008(0.68%)
Mkt cap ! $1.278B
Open High Low Value Volume
$1.13 $1.16 $1.10 $5.176M 4.627M

Buyers (Bids)

No. Vol. Price($)
22 67714 $1.11
 

Sellers (Offers)

Price($) Vol. No.
$1.12 39353 13
View Market Depth
Last trade - 13.44pm 08/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.